A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers

被引:2
|
作者
Chen, Qingwang [1 ,2 ]
Liu, Yaqing [1 ,2 ]
Gao, Yuechen [1 ,2 ]
Zhang, Ruolan [1 ,2 ]
Hou, Wanwan [1 ,2 ]
Cao, Zehui [1 ,2 ]
Jiang, Yi-Zhou [3 ]
Zheng, Yuanting [1 ,2 ]
Shi, Leming [1 ,2 ,4 ,5 ]
Ma, Ding [3 ]
Yang, Jingcheng [1 ,2 ,6 ]
Shao, Zhi-Ming [3 ]
Yu, Ying [1 ,2 ]
机构
[1] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China
[2] Fudan Univ, Human Phenome Inst, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Key Lab Breast Canc Shanghai, Dept Breast Surg,Precis Canc Med Ctr, Shanghai, Peoples R China
[4] Fudan Univ, Shanghai Canc Hosp, Canc Inst, Shanghai 200438, Peoples R China
[5] Fudan Univ, Fudan Gospel Joint Res Ctr Precis Med, Shanghai 200438, Peoples R China
[6] Greater Bay Area Inst Precis Med, Guangzhou, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
RNA-SEQ; ALIGNMENT; SUBTYPES; HISAT;
D O I
10.1038/s41597-022-01681-z
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Molecular subtyping of triple-negative breast cancer (TNBC) is essential for understanding the mechanisms and discovering actionable targets of this highly heterogeneous type of breast cancer. We previously performed a large single-center and multiomics study consisting of genomics, transcriptomics, and clinical information from 465 patients with primary TNBC. To facilitate reusing this unique dataset, we provided a detailed description of the dataset with special attention to data quality in this study. The multiomics data were generally of high quality, but a few sequencing data had quality issues and should be noted in subsequent data reuse. Furthermore, we reconduct data analyses with updated pipelines and the updated version of the human reference genome from hg19 to hg38. The updated profiles were in good concordance with those previously published in terms of gene quantification, variant calling, and copy number alteration. Additionally, we developed a user-friendly web-based database for convenient access and interactive exploration of the dataset. Our work will facilitate reusing the dataset, maximize the values of data and further accelerate cancer research.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] TTK: A novel target for radiosensitization in triple-negative breast cancers
    Chandler, Benjamin C.
    Moubadder, Leah
    Ritter, Cassie
    Niknafs, Yashar
    Olsen, Eric
    Cameron, Meleah
    Liu, Meilan
    Wilder-Romans, Kari
    Nyati, Shyam
    Brown, Powel
    Chinnaiyan, Arul
    Speers, Corey
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [42] Triple-Negative Breast Cancers: Unique Clinical Presentations and Outcomes
    Billar, Julie A. Y.
    Dueck, Amylou C.
    Stucky, Chee-Chee H.
    Gray, Richard J.
    Wasif, Nabil
    Northfelt, Donald W.
    McCullough, Ann E.
    Pockaj, Barbara A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S384 - S390
  • [43] Targeting a cell state common to triple-negative breast cancers
    Muellner, Markus K.
    Mair, Barbara
    Ibrahim, Yasir
    Kerzendorfer, Claudia
    Lechtermann, Hannelore
    Trefzer, Claudia
    Klepsch, Freya
    Mueller, Andre C.
    Leitner, Ernestine
    Macho-Maschler, Sabine
    Superti-Furga, Giulio
    Bennett, Keiryn L.
    Baselga, Jose
    Rix, Uwe
    Kubicek, Stefan
    Colinge, Jacques
    Serra, Violeta
    Nijman, Sebastian M. B.
    [J]. MOLECULAR SYSTEMS BIOLOGY, 2015, 11 (02)
  • [44] Pathway Analysis of Primary Human Triple-Negative Breast Cancers
    Ossovskaya, V.
    Xu, Q.
    Lituev, A.
    Potapova, O.
    Monforte, J.
    Daraselia, N.
    [J]. CANCER RESEARCH, 2010, 70
  • [45] GATA3 expression in triple-negative breast cancers
    Byrne, David J.
    Deb, Siddhartha
    Takano, Elena A.
    Fox, Stephen B.
    [J]. HISTOPATHOLOGY, 2017, 71 (01) : 63 - 71
  • [46] Imputing a more targeted therapy for triple-negative breast cancers
    Gruener, Robert F.
    Greene, Geoffrey L.
    Huang, R. Stephanie
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (12) : 25 - 26
  • [47] Efavirenz as a potential drug for the treatment of triple-negative breast cancers
    Chiou, P-T
    Ohms, S.
    Board, P. G.
    Dahlstrom, J. E.
    Rangasamy, D.
    Casarotto, M. G.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (02): : 353 - 363
  • [48] Triple-Negative Breast Cancers: Unique Clinical Presentations and Outcomes
    Yee, Julie
    Dueck, Amylou
    Stucky, Chee-Chee
    Gray, Richard
    Wasif, Nabil
    Northfelt, Donald
    McCullough, Ann
    Pockaj, Barbara
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (02) : S156 - S156
  • [49] What Is the Difference Between Triple-Negative and Basal Breast Cancers?
    Seal, Melanie D.
    Chia, Stephen K.
    [J]. CANCER JOURNAL, 2010, 16 (01): : 12 - 16
  • [50] Classification of triple-negative breast cancers based on Immunogenomic profiling
    Yin He
    Zehang Jiang
    Cai Chen
    Xiaosheng Wang
    [J]. Journal of Experimental & Clinical Cancer Research, 37